ClinicalTrials.gg
RecruitingNCT06677151Updated Nov 18, 2026

NPA-OSA Device Tolerability, Usability and Acclimation Clinical Study in Adult Obstructive Sleep Apnea (OSA) Patients

An interventional study of nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device in Sleep Apnea, Obstructive, sponsored by University of Michigan. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Michigan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Sleep Apnea, Obstructive by University of Michigan — 5 open to participants now, 5 under way, none of them phase 3. Sleep Apnea, Obstructive · University of Michigan.

Planned enrollment
13th of 17
20 · median 40
Started
2025
with 1 other
No phase
13 of 21
5 open now
Registered
20th of 21
by date

Among the 21 studies in Sleep Apnea, Obstructive by University of Michigan, this one is the 13th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 with no phase, and was the 20th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

5 of the 21 studies in Sleep Apnea, Obstructive by University of Michigan are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Sleep Apnea, Obstructive by University of Michigan, or all of them as a file.
02

Study summary

This pilot study is being done to determine if the nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device can be used in the treatment of OSA in adults. The researchers think that the NPA-OSA device will reduce the number of apneas.

03

Conditions studied

  • Sleep Apnea, Obstructive

Keywords

  • nasopharyngeal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capacity and willingness to sign consent
  • Patient willingness to commit to and complete study over a 30-day time period
  • Confirmed diagnosis of moderate to severe OSA (AHI >= 15)
  • OSA caused by upper airway obstruction
  • CPAP non-compliant where CPAP compliance is defined as using CPAP for at least 4 hours a night for at least 70% of nights or interest in an alternative sleep apnea therapy
  • Adequate manual dexterity to demonstrate ability to self-insert and remove device

Exclusion criteria

Exclusion Criteria:

  • Within 3 months of initiating CPAP use, and actively using CPAP
  • Supraglottic airway collapse
  • Distal airway stenosis
  • Tracheobronchomalacia
  • Currently pregnant
  • Active COVID-19 infection
  • Need for anticoagulative therapy
  • Severe nasal allergies
  • Bleeding disorder
  • More than mild elevation of End-tidal carbon dioxide (ETCO2) or total carbon dioxide (TCO2) values >60 mmHg for >10% of sleep time
  • Restrictive thoracic disorders
  • Silicone, lidocaine, neosynephrine allergy
  • Recurrent epistaxis
  • Uncontrolled or serious illness, included but not limited to: severe breathing disorders including hypercapnic respiratory failure, respiratory muscle weakness, bullous lung disease (as seen in some types of emphysema), bypassed upper airway, pneumothorax, pneumomediastinum, etc.; severe heart disease (including heart failure); or pathologically low blood pressure
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Nasopharyngeal airway device

    A nasopharyngeal airway obstructive sleep apnea ("NPA"-OSA) device will be used for one night in a sleep laboratory and 30 days at home.

    Device: nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device

Interventions

  • Devicenasopharyngeal airway obstructive sleep apnea (NPA-OSA) device

    The NPA-OSA is a flexible, medical-grade silicone, tube-like device that is self-inserted into the user's nasopharyngeal airway through one nostril prior to sleep and worn throughout the night to reduce or alleviate snoring and obstructive sleep apnea.

06

What researchers measure

Primary outcomes

  1. Change in severity of apnea hypopnea index (AHI)

    The AHI is calculated by dividing the number of apnea events by the number of hours of sleep.

    Time frame: Baseline (day 0), 30 days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Oct 2027, 31 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 31 months is close to that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Oct 2026 → Oct 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 6, 2024
StartActual
Mar 7, 2025
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Oct 2027
Nov 18, 2026
Study completion
Dec 2026→Dec 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Oct 2026→Oct 2027
    Study completion Dec 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06677151
Collaborators
Wallace H Coulter Center for Translational Research
Responsible party
Louise O'Brien (Professor, Sleep Medicine, University of Michigan) — Principal investigator
First posted
Nov 6, 2024
Start date
Mar 7, 2025
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Zahra Nourmohammadi, PhD
Contact
znourmoh@med.umich.edu
734 936-9816
Louise M O'Brien, PhD
Contact
louiseo@med.umich.edu
734 647-9064
Louise M O'Brien, PhD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion